Search Results - "Jost, Lorenz"

Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients – evaluation of outcome and prognostic factors: A retrospective multicenter study by Fuchs, Julia, Früh, Martin, Papachristofilou, Alexandros, Bubendorf, Lukas, Häuptle, Pirmin, Jost, Lorenz, Zippelius, Alfred, Rothschild, Sacha I.

“…Background and objectives Brain metastases occur in about 30% of all patients with non-small cell lung cancer (NSCLC). In selected patients, long-term survival…”
Get full text

Intra-Abdominal Nocardiosis—Case Report and Review of the Literature by Tramèr, Lucas, Mertz, Kirsten D., Huegli, Rolf, Hinic, Vladimira, Jost, Lorenz, Burkhalter, Felix, Wirz, Sebastian, Tarr, Philip E.

“…Nocardiosis is primarily an opportunistic infection affecting immunosuppressed individuals, in whom it most commonly presents as pulmonary infection and…”
Get full text

Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial by Stupp, Roger, Dr, Mayer, Michael, PhD, Kann, Roger, MD, Weder, Walter, Prof, Zouhair, Abderahim, MD, Betticher, Daniel C, Prof, Roth, Arnaud D, MD, Stahel, Rolf A, Prof, Majno, Sabine Balmer, MD, Peters, Solange, MD-PhD, Jost, Lorenz, MD, Furrer, Markus, Prof, Thierstein, Sandra, Schmid, Ralph A, Prof, Hsu-Schmitz, Shu-Fang, PhD, Mirimanoff, René-Olivier, Prof, Ris, Hans-Beat, Prof, Pless, Miklos, MD

“…Summary Background Stage IIIB non-small-cell lung cancer (NSCLC) is usually thought to be unresectable, and is managed with chemotherapy with or without…”
Get full text

Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients by JOST, Lorenz M, GSCHWIND, Hans-Peter, MASSON, Eric, LAURENT, Dirk, JALAVA, Tarja, YONGYU WANG, GUENTHER, Clemens, SOUPPART, Claire, ROTTMANN, Antje, DENNER, Karsten, WALDMEIER, Felix, GROSS, Gerhard

“…Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under…”
Get full text

Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors by Wickremsinhe, Enaksha R., Hynes, Scott M., Palmieri, Margo D., Mitchell, Malcolm I., Abraham, Trent L., Rehmel, Jessica Fayer, Chana, Emilie, Jost, Lorenz M., Cassidy, Kenneth C.

“…Abstract 1. The disposition and metabolism of a Chk-1 inhibitor (LY2603618) was characterized following a 1-h intravenous administration of a single 250-mg…”
Get full text

Resection of isolated brain metastases in non-small cell lung cancer by Fuchs, Julia, Früh, Martin, Papachristofilou, Alexandros, Bubendorf, Lukas, Häuptle, Pirmin, Jost, Lorenz, Zippelius, Alfred, Rothschild, Sacha I

“…Background and objectives Brain metastases occur in about 30% of all patients with non-small cell lung cancer (NSCLC). In selected patients, long-term survival…”
Get full text

Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Get full text

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Get full text

Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study by Kasenda, Benjamin, Bass, Annatina, Koeberle, Dieter, Pestalozzi, Bernhard, Borner, Markus, Herrmann, Richard, Jost, Lorenz, Lohri, Andreas, Hess, Viviane

“…Obesity is a risk factor for developing pancreatic cancer. We investigated the impact of obesity on survival in patients diagnosed with locally advanced or…”
Get full text

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy by Zucca, Emanuele, Rondeau, Stephanie, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich J.M., Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, de Nully Brown, Peter, Hagberg, Hans, Ferreri, Andrés J.M., Lohri, Andreas, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Bargetzi, Mario, Mingrone, Walter, Krasniqi, Fatime, Dirnhofer, Stefan, Hayoz, Stefanie, Hawle, Hanne, Vilei, Simona Berardi, Ghielmini, Michele, Kimby, Eva

“…The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs…”
Get full text

Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic by Vujanovic, N L, Rabinowich, H, Lee, Y J, Jost, L, Herberman, R B, Whiteside, T L

“…Human natural killer (NK) cells can be functionally subdivided into adherent (A) and non-adherent (NA) subpopulations. In the presence of 22 nM of interleukin…”
Get more information

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016 by Dittrich, C., Kosty, M., Jezdic, S., Pyle, D., Berardi, R., Bergh, J., Lotz, J.-P., Österlund, P., Pavlidis, N., Purkalne, G., Carraway, Hetty, Lee Close, Julia, Gilbert, Jill, Bokemeyer, Carsten, Cervantes, Andrés, Ohe, Yuichiro, Pless, Miklos, McGregor, Keith, Fumassoli, Katharine, Candiani, Roberta, Bricalli, Gracemarie, Kenny, Tanya, Latino, Nicola, Cogo, Marina, Pavinato, Vanessa, Marchesi, Vanessa, Awada, Ahmad, Banerjee, Susana, Bhatia, Smita, Bogaerts, Jan, Buckner, Jan, Cardoso, Fatima, Casali, Paolo, Chu, Edward, Coiffier, Bertrand, Connolly, Roisin, Coupland, Sarah, De Petris, Luigi, De Santis, Maria, de Vries, Elisabeth G.E., Dizon, Don S., Duff, Jennifer, Duska, Linda R., Eniu, Alexandru, Ernstoff, Marc, Felip, Enriqueta, Fey, Martin F., Glaudemans, Andor W.J.M., Gopalan, Priya K., Grothey, Axel, Hahn, Stephen M., Hanna, Diana, Herold, Christian, Herrstedt, Jørn, Homicsko, Krisztian, Jones, Dennie V., Jost, Lorenz, Keilholz, Ulrich, Khan, Saad, Kiss, Alexander, Köhne, Claus-Henning, Kunstfeld, Rainer, Lichtman, Stuart, Licitra, Lisa, Lion, Thomas, Litière, Saskia, Loehrer, Patrick J., Jennifer Markham, Merry, Markman, Ben, Mayerhoefer, Marius, Meran, Johannes G., Michielin, Olivier, Charlotte Moser, Elizabeth, Mountzios, Giannis, Moynihan, Timothy, Palumbo, Antonio, Alessandro Peccatori, Fedro, Pfeilstöcker, Michael, Raut, Chandrajit, Remick, Scot C., Rutkowski, Piotr, Salgado, Roberto, Schernhammer, Eva, Schlumberger, Martin, Schmoll, Hans-Joachim, Schnipper, Lowell, Sessa, Cristiana, Shapiro, Charles L., Steele, Julie, Sternberg, Cora N., Stiefel, Friedrich, Sullivan, Richard, Tabernero, Josep, Travado, Luzia, Verheij, Marcel, Voest, Emile, Von Roenn, Jamie, Weber, Jeffrey S., Wildiers, Hans, Yarden, Yosef

Get full text

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial by Huober, Jens, Weder, Patrik, Ribi, Karin, Thürlimann, Beat, Thery, Jean-Christophe, Li, Qiyu, Vanlemmens, Laurence, Guiu, Séverine, Brain, Etienne, Grenier, Julien, Dalenc, Florence, Levy, Christelle, Savoye, Aude-Marie, Müller, Andreas, Membrez-Antonioli, Véronique, Gérard, Marie-Aline, Lemonnier, Jérôme, Hawle, Hanne, Dietrich, Daniel, Boven, Epie, Bonnefoi, Hervé

“…In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with taxane-based chemotherapy is the first line of…”
Get more information

Psoas Abscess Due to Mycobacterium avium in A Patient with Chronic Lymphocytic Leukemia－Case Report and Review by Diaco, Natascha D, Strohdach, Bettina, Falkowski, Anna L, Hainc, Nicolin, Brunner, Philippe, Rutishauser, Jonas, Jost, Lorenz, Tarr, Philip E

“…Infections may constitute a serious complication in patients with chronic lymphocytic leukemia (CLL). New treatment agents including obinutuzumab and ibrutinib…”
Get full text

Y90‐Ibritumomab tiuxetan (Y90‐IT) and high‐dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05) by Voegeli, Michèle, Rondeau, Stephanie, Berardi Vilei, Simona, Lerch, Erika, Wannesson, Luciano, Pabst, Thomas, Rentschler, Jochen, Bargetzi, Mario, Jost, Lorenz, Ketterer, Nicolas, Bischof Delaloye, Angelika, Ghielmini, Michele

“…Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high‐dose…”
Get full text

Y 90 -Ibritumomab tiuxetan (Y 90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05) by Voegeli, Michèle, Rondeau, Stephanie, Berardi Vilei, Simona, Lerch, Erika, Wannesson, Luciano, Pabst, Thomas, Rentschler, Jochen, Bargetzi, Mario, Jost, Lorenz, Ketterer, Nicolas, Bischof Delaloye, Angelika, Ghielmini, Michele

“…Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high-dose…”
Get full text

Y 90 -ibritumomab tiuxetan (Y 90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation (ASCT) for elderly patients with lymphoma in relapse or resistant to chemotherapy: A feasibility trial (SAKK 37/05) by Voegeli, Michele, Rondeau, Stephanie, Berardi, Simona, Lerch, Erika, Wannesson, Luciano, Pabst, Thomas, Rentschler, Jochen, Bargetzi, Mario, Jost, Lorenz M., Ketterer, Nicolas, Bischof Delaloye, Angelika, Ghielmini, Michele E. G.

“…Abstract only 8560 Background: Standard conditioning regimens for ASCT are often not tolerated by elderly patients. Single agent high-dose melphalan has been…”
Get full text

P-606 Neoadjuvant chemo- and radiotherapy for stage IIIB non-small cell lung cancer (NSCLC). A prospective multicenter trial by the Swiss group for clinical cancer research (SAKK) by Stupp, Roger, Stahel, Rolf A., Kann, Roger, Betticher, Daniel, Zouhair, Abderrahim, Jost, Lorenz, Rufibach, Kaspar, Thierstein, Sandra, Ris, Hans B., Pless, Miklos

Get full text

Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies by Stahel, R A, Jost, L M, Cerny, T, Pichert, G, Honegger, H, Tobler, A, Jacky, E, Fey, M, Platzer, E

“…The aim of this prospective randomized trial was to examine the efficacy and safety of filgrastim after high-dose chemotherapy and autologous bone marrow…”
Get more information

A prospective study of risk-adapted therapy for large cell not-Hodgkin's lymphoma wit VACOP-B followed by high-dose CBV and autologous progenitor cell transplant for high-risk patients in remission by Stahel, Rolf A, Jost, Lorenz M, Kroner, Thomas, Dammann-Scherrer, Corina

Get full text